{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:50:23Z","timestamp":1791276623883,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirikizumab (MIR), a selective interleukin-23p19 inhibitor, has demonstrated efficacy in randomized trials for moderate-to-severe ulcerative colitis (UC). Real-world data remain limited. Here, we evaluated the effectiveness, durability, and safety of MIR in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, multicentre cohort study of adults with UC initiating MIR at two tertiary centres in Canada. Clinical, biomarker, endoscopic, and safety outcomes were assessed at weeks 12, 28, and 52. The primary outcome was corticosteroid-free (CSF) clinical remission at week 12. Secondary outcomes included CSF clinical remission at weeks 28 and 52, CSF clinical response, mucosal healing, treatment persistence, extended induction, and serious adverse events. Predictors of extended induction were evaluated using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-two patients were included; 94% were previously exposed to at least one advanced therapy. CSF clinical remission was achieved in 24% of patients at week 12, 35% at weeks 28, and 33% at week 52, with corresponding CSF clinical response rates of 45%, 53%, and 40%. Moreover, 40% of the cohort received extended induction. In the extended induction subgroup, CSF clinical remission was observed in 19% at week 28 and 22% at week 52, with CSF clinical response rates observed in 37% and 30%, respectively. Early CSF clinical response at week 12 was associated with treatment persistence. The incidence of serious adverse events was low, with no new safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this multicentre real-world Canadian cohort of predominantly treatment-experienced patients with UC, MIR demonstrated clinically relevant effectiveness, acceptable durability, and a favourable safety profile over 1 year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jcag\/gwag023","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:55:28Z","timestamp":1781870128000},"page":"312-319","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and predictors of need for extended induction of mirikizumab therapy in ulcerative colitis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8812-4777","authenticated-orcid":false,"given":"Cathy","family":"McShane","sequence":"first","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Kalisky","sequence":"additional","affiliation":[{"name":"IBD Centre of BC , Vancouver, BC V6Z 2L2,","place":["Canada"]},{"name":"Division of Gastroenterology, University of British Columbia , Vancouver, BC V6T 1Z7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9727-701X","authenticated-orcid":false,"given":"Jonah S","family":"Moore","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Milgrom","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Stempak","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-6102","authenticated-orcid":false,"given":"Pablo A","family":"Olivera","sequence":"additional","affiliation":[{"name":"Unity Health Toronto , Toronto, ON M5C 2T2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-0180","authenticated-orcid":false,"given":"Kenneth","family":"Croitoru","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian W","family":"Huang","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura E","family":"Targownik","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam V","family":"Weizman","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zane","family":"Gallinger","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-0047","authenticated-orcid":false,"given":"Sun-Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"IBD Centre of BC , Vancouver, BC V6Z 2L2,","place":["Canada"]},{"name":"Division of Gastroenterology, University of British Columbia , Vancouver, BC V6T 1Z7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto, ON M5G 1X5,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3G9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026100603513499500_gwag023-B1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2026100603513499500_gwag023-B2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","article-title":"What does disease progression look like in ulcerative colitis, and how might it Be prevented?","volume":"162","author":"Krugliak Cleveland","year":"2022","journal-title":"Gastroenterology"},{"key":"2026100603513499500_gwag023-B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12876-023-02675-w","article-title":"Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn\u2019s disease and ulcerative colitis in the United States","volume":"23","author":"Gibble","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"Suppl. 3","key":"2026100603513499500_gwag023-B4","first-page":"9","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study","volume":"19","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026100603513499500_gwag023-B5","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100603513499500_gwag023-B6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"2026100603513499500_gwag023-B7","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.14309\/ajg.0000000000003670","article-title":"Patients included in clinical trials of biological drugs for inflammatory bowel disease do not represent the real-world population","volume":"121","author":"Casas Deza","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"2026100603513499500_gwag023-B8","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"2026100603513499500_gwag023-B9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"2026100603513499500_gwag023-B10","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2026100603513499500_gwag023-B11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026100603513499500_gwag023-B12","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/apt.70140","article-title":"Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study","volume":"61","author":"Takagi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100603513499500_gwag023-B13","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center","volume":"70","author":"St-Pierre","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026100603513499500_gwag023-B14","doi-asserted-by":"publisher","first-page":"17562848251392074","DOI":"10.1177\/17562848251392074","article-title":"Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study","volume":"18","author":"Levartovsky","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"2026100603513499500_gwag023-B15","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2025.00176","article-title":"Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan","author":"Mizushima","year":"2026","journal-title":"Intest Res"},{"key":"2026100603513499500_gwag023-B16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/ibd\/izae004","article-title":"Extended induction and prognostic indicators of response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials","volume":"30","author":"D\u2019Haens","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026100603513499500_gwag023-B17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026100603513499500_gwag023-B18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","article-title":"Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: Results from phase III LUCENT studies","volume":"62","author":"Chua","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026100603513499500_gwag023-B19","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s12325-025-03158-y","article-title":"Pharmacokinetic comparability and safety between original and citrate-free mirikizumab formulations for subcutaneous injections: Results from three clinical trials","volume":"42","author":"Otani","year":"2025","journal-title":"Adv Ther"},{"key":"2026100603513499500_gwag023-B20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026100603513499500_gwag023-B21","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/jcag\/gwae058","article-title":"A practical approach to positioning therapies in ulcerative colitis","volume":"8","author":"Yanofsky","year":"2025","journal-title":"J Can Assoc Gastroenterol"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/9\/5\/312\/68668198\/gwag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/9\/5\/312\/68668198\/gwag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:39Z","timestamp":1791273099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/9\/5\/312\/8723172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwag023","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,1]]}}}